Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 12:41 pm Sale | 2022-12-31 | 13G | PHAXIAM THERAPEUTICS S.A. AMER PHXM | Armistice Capital, LLC | 162,912 4.990% | -110,813 (-40.48%) | Filing History |
| 2023-02-13 6:08 pm Sale | 2022-12-31 | 13G | PHAXIAM THERAPEUTICS S.A. AMER PHXM | BIOTECHNOLOGY VALUE FUND L P | 51,724 1.600% | -178,206 (-77.50%) | Filing History |
| 2022-12-23 5:08 pm Sale | 2022-12-21 | 13G | PHAXIAM THERAPEUTICS S.A. AMER PHXM | BIOTECHNOLOGY VALUE FUND L P | 229,930 7.400% | -281,988 (-55.08%) | Filing History |
| 2022-02-14 6:28 pm Purchase | 2021-12-31 | 13G | PHAXIAM THERAPEUTICS S.A. AMER PHXM | Armistice Capital, LLC | 273,725 9.300% | 273,725 (New Position) | Filing History |
| 2022-02-14 1:49 pm Purchase | 2021-12-31 | 13G | PHAXIAM THERAPEUTICS S.A. AMER PHXM | BIOTECHNOLOGY VALUE FUND L P | 511,918 16.500% | 103,724 (+25.41%) | Filing History |